GLP-1 agonists may increase survival in colon cancer patients.
(We’ve known for a long time that calorie restriction slows growth of various cancers in animal models.)
Medscape reports a real-world analysis of nearly 7,000 colon cancer patients in which those on a GLP-1 receptor agonist were less than half as likely to die within 5 years. Louis links this to calorie restriction effects seen in animals.
GLP-1 agonists may increase survival in colon cancer patients.
(We’ve known for a long time that calorie restriction slows growth of various cancers in animal models.)
Treatment with a GLP-1 receptor agonist (RA) may offer a survival advantage in patients with colon cancer and obesity.
In a real-world analysis of nearly 7000 patients with colon cancer, those taking a GLP-1 RA were less than half as likely to die within 5 years compared with those who weren’t on a GLP-1 drug. GLP-1s May Improve Colon Cancer Outcomes (Medscape)